Docstoc

Aarkstore Enterprise-ZIOPHARM Oncology, Inc. – Product Pipeline Review – 2012

Document Sample
Aarkstore Enterprise-ZIOPHARM Oncology, Inc. – Product Pipeline Review – 2012 Powered By Docstoc
					Aarkstore.com announces, The Latest market research report is available in
its vast collection:

ZIOPHARM Oncology, Inc. – Product Pipeline Review – 2012



More about this report http://www.aarkstore.com/reports/ZIOPHARM-
Oncology-Inc-Product-Pipeline-Review-2012-225177.html



You can also request for sample page of above mention reports on
sample@aarkstore.com


Summary

Global Markets Direct’s pharmaceuticals report, “ZIOPHARM Oncology, Inc. -
Product Pipeline Review - 2012” provides data on the ZIOPHARM Oncology, Inc.’s
research and development focus. The report includes information on current
developmental pipeline, complete with latest updates, and features on discontinued
and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s
proprietary databases, ZIOPHARM Oncology, Inc.’s corporate website, SEC filings,
investor presentations and featured press releases, both from ZIOPHARM Oncology,
Inc. and industry-specific third party sources, put together by Global Markets
Direct’s team.

Scope

- ZIOPHARM Oncology, Inc. - Brief ZIOPHARM Oncology, Inc. overview including
business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of ZIOPHARM Oncology, Inc. human therapeutic
division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development,
including the combination treatment modalities, across the globe.

Table of contents:

List of Tables 5
List of Figures 5
ZIOPHARM Oncology, Inc. Snapshot 6
ZIOPHARM Oncology, Inc. Overview 6
Key Information 6
Key Facts 6
ZIOPHARM Oncology, Inc. – Research and Development Overview 7
Key Therapeutic Areas 7
ZIOPHARM Oncology, Inc. – Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products – Monotherapy 11
Pipeline Products – Combination Treatment Modalities 12
ZIOPHARM Oncology, Inc. – Pipeline Products Glance 13
ZIOPHARM Oncology, Inc. – Late Stage Pipeline 13
Phase III Products/Combination Treatment Modalities 13
ZIOPHARM Oncology, Inc. Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
Phase I Products/Combination Treatment Modalities 15
ZIOPHARM Oncology, Inc. – Early Stage Pipeline Products 16
Pre-Clinical Products/Combination Treatment Modalities 16
ZIOPHARM Oncology, Inc. – Drug Profiles 17
Ad-IL-12 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
DC-IL-12 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
indibulin + erlotinib hydrochloride 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
palifosfamide 22
Product Description 22



List of Figures

List of Tables are also include.



For more related Reports Plz follow The link:

Product Pipeline Review – 2012
http://www.aarkstore.com/search/viewresults.asp?search=Product Pipeline
Review – 2012&PubId=&pagenum=1




MacroGenics, Inc. – Product Pipeline Review – 2012

TopoTarget A/S – Product Pipeline Review – 2012

YM BioSciences Inc. – Product Pipeline Review – 2012

ZIOPHARM Oncology, Inc. – Product Pipeline Review – 2012

Zydus Cadila Healthcare Limited – Product Pipeline Review – 2012

Acucela Inc. – Product Pipeline Review – 2012

Aldagen, Inc. – Product Pipeline Review – 2012

Bellicum Pharmaceuticals, Inc. – Product Pipeline Review – 2012
DiaKine Therapeutics, Inc. – Product Pipeline Review – 2012

Dong-A Pharmaceutical Co., Ltd. – Product Pipeline Review – 2012




Search More Reports Related to This Category :


Pharmaceuticals and Healthcare
http://www.aarkstore.com/search/viewresults.asp?search=Pharmaceuticals and
Healthcare&PubId=&pagenum=1




For More details Plz do contact :

Aarkstore Enterprise

Lavanya

Phone:08149852585

Email: enquiry@aarkstore.com

				
DOCUMENT INFO
Shared By:
Categories:
Stats:
views:3
posted:9/27/2012
language:
pages:4